Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Barbara Lima,Miguel Henriques Abreu,Susana Sousa,Carla Bartosch,Deolinda Pereira

Gynecologic oncology reports（2022）

引用 2|浏览0

暂无评分

摘要

•LGSOC is characterized scarce therapeutic options in the advanced setting.•BRAF mutations are frequent on these types of tumours.•Dabrafenib/trametinib yield impressive responses in patients with BRAF mutations.

查看译文

关键词

Low-grade serous ovarian cancer,BRAF mutation,Dabrafenib,Trametinib,Combination treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要